Evidence map›Paper›PMID 38634567›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

Tau Aggregation-Dependent Lipid Peroxide Accumulation Driven by the hsa_circ_0001546/14-3-3/CAMK2D/Tau Complex Inhibits Epithelial Ovarian Cancer Peritoneal Metastasis.

BinShu Chai, Yong Wu, HengHui Yang, BiaoFeng Fan, SiYu Cao, XiaoFei Zhang, YaQing Xie, ZhiXiang Hu, ZhongLiang Ma, YunKui Zhang and 8 more

Open access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Circular RNAs in ferroptosis regulation and tumor progression of gynecological and breast cancers: molecular mechanisms and therapeutic potential.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

BinShu ChaiDepartment of Gynecology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Center, Kunming, 650118, China.
Yong WuDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
HengHui YangDepartment of Gynecology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Center, Kunming, 650118, China.
BiaoFeng FanDepartment of Gynecology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Center, Kunming, 650118, China.
SiYu CaoDepartment of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
XiaoFei ZhangDepartment of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, 2699 West Gaoke Road, Shanghai, 201204, China.
YaQing XieDepartment of Gynecology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Center, Kunming, 650118, China.
ZhiXiang HuDepartment of Integrative Oncology, Fudan University Shanghai Cancer Center, and Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China.
ZhongLiang MaLab for Noncoding RNA & Cancer, School of Life Sciences, Shanghai University, Shanghai, 200444, China.
YunKui ZhangDepartment of Anesthesiology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Wei PanLab for Noncoding RNA & Cancer, School of Life Sciences, Shanghai University, Shanghai, 200444, China.
Wei MengLab for Noncoding RNA & Cancer, School of Life Sciences, Shanghai University, Shanghai, 200444, China.
Jiao MengDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
WenJuan TianDepartment of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
JiaLi ZhangCancer Institute, Fudan University Shanghai Cancer Center, and Shanghai Fifth People's Hospital, Shanghai, 200032, China.
YanLi LiLab for Noncoding RNA & Cancer, School of Life Sciences, Shanghai University, Shanghai, 200444, China.
Yang ShaoDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.ORCID 0000-0002-3239-4265
ShaoJia WangDepartment of Gynecology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Center, Kunming, 650118, China.
Fudan University Shanghai Cancer Center · CNShanghai University · CNKunming Medical University · CNShanghai Medical College of Fudan University · CNShanghai First Maternity and Infant Hospital · CN

Funding

National Natural Science Foundation of China 82002726National Natural Science Foundation of China 82002758National Natural Science Foundation of China 82203714National Natural Science Foundation of China 82260577Young and Middle-aged Reserve Academic and Technical Leaders in Yunnan Province CZ0165Yunnan Provincial Medical Reserve Talents Project H-2019007
6 · The paper itself

Abstract

Intraperitoneal dissemination is the main method of epithelial ovarian cancer (EOC) metastasis, which is related to poor prognosis and a high recurrence rate. Circular RNAs (circRNAs) are a novel class of endogenous RNAs with covalently closed loop structures that are implicated in the regulation of tumor development. In this study, hsa_circ_0001546 is downregulated in EOC primary and metastatic tissues vs. control tissues and this phenotype has a favorable effect on EOC OS and DFS. hsa_circ_0001546 can directly bind with 14-3-3 proteins to act as a chaperone molecule and has a limited positive effect on 14-3-3 protein stability. This complex recruits CAMK2D to induce the Ser324 phosphorylation of Tau proteins, changing the phosphorylation status of Tau bound to 14-3-3 and ultimately forming the hsa_circ_0001546/14-3-3/CAMK2D/Tau complex. The existence of this complex stimulates the production of Tau aggregation, which then induces the accumulation of lipid peroxides (LPOs) and causes LPO-dependent ferroptosis. In vivo, treatment with ferrostatin-1 and TRx0237 rescued the inhibitory effect of hsa_circ_0001546 on EOC cell spreading. Therefore, based on this results, ferroptosis caused by Tau aggregation occurs in EOC cells, which is not only in Alzheimer's disease- or Parkinson's disease-related cells and this kind of ferroptosis driven by the hsa_circ_0001546/14-3-3/CAMK2D/Tau complex is LPO-dependent rather than GPX4-dependent is hypothesized.

Indexed as

Carcinoma, Ovarian EpithelialOvarian NeoplasmsRNA, Circulartau Proteins14-3-3 ProteinsAnimalsCell Line, TumorDisease Models, AnimalFemaleHumansLipid PeroxidationMicePeritoneal Neoplasms14-3-3 ProteinsRNA, Circulartau Proteins14‐3‐3epithelial ovarian cancerferroptosislipid peroxideTau

Identifiers

PMID38634567
PMCPMC11186043
OpenAlexW4394920633

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.